HALOZYME THERAPEUTICS, INC. HALO

Healthcare SIC 2836 - Biological Products, (No Diagnostic Substances) NAICS Manufacturing › Chemical Manufacturing › Pharmaceutical and Medicine Manufacturing › Biological Product (except Diagnostic) Manufacturing derived Nasdaq

Halozyme Therapeutics, Inc. is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies.

As the innovators of ENHANZE® drug delivery technology ("ENHANZE") with our proprietary enzyme, rHuPH20, our commercially validated solution is used to facilitate the subcutaneous ("SC") delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. We license our technology to biopharmaceutical companies to collaboratively develop products that combine ENHANZE with our partners' proprietary compounds. We are also developing partner products with Hypercon™ drug delivery technology ("Hypercon technology") and developing the Surf Bio drug delivery technology to expand the breadth of our drug delivery technology portfolio. Hypercon technology is an innovative microparticle technology that has been demonstrated in non-clinical testing to enable hyperconcentration of drugs and biologics and reduce the injection volume for the same dosage, potentially expanding opportunities for at-home and health care provider administration. The Surf Bio hyperconcentration technology is being developed to create high antibody and biologic concentrations of up to 500 mg/mL, for delivery in a single auto-injector shot for at-home or in a health care provider's office use. We also develop, manufacture and commercialize, for ourselves or with our partners, drug-device combination products using our advanced auto-injector technologies that are designed to provide commercial or functional advantages such as improved convenience, reliability and tolerability, and enhanced patient comfort and adherence.

Last close 125.63 2026-10-23
Market cap $14.26B 2026-06-30 share count
52-week range 61.23 - 126.23

Valuation FY2025 figures against the last close

P/S10.2x
P/E49.1x
P/FCF22.1x
EV/EBITDA33.9x
Dividend yield—
Diluted EPS2.56

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue $1.40B$1.02B$829.3M$660.1M$443.3M$267.6M$196.0M$151.9M$316.6M$146.7M
Cost of revenue $228.8M$159.4M$192.4M$139.3M$81.4M$43.4M$45.5M$10.1M$31.2M$33.2M
Gross profit $1.17B$855.9M$636.9M$520.8M$361.9M$224.2M$150.4M$141.7M$285.5M$113.5M
R&D —$79.0M$76.4M$66.6M$35.7M$34.2M$140.8M$150.3M$150.6M$150.8M
SG&A $207.1M$154.3M$149.2M$143.5M$50.3M$45.7M$77.3M$60.8M$53.8M$45.9M
Total operating expenses $927.6M$463.8M$491.7M$392.6M$167.4M$123.3M$263.6M$221.2M$235.6M$229.9M
Operating income $469.0M$551.5M$337.6M$267.5M$275.9M$144.3M-$67.6M-$69.3M$81.0M-$83.2M
Interest expense $18.1M$18.1M$18.8M$16.9M$7.5M$20.4M$11.6M$18.0M$22.0M$20.0M
Pre-tax income $466.9M$557.1M$348.3M$248.9M$248.5M$129.3M-$72.3M-$79.8M$61.6M-$101.9M
Income tax $150.0M$113.0M$66.7M$46.8M$154.2M$217.0K$11.0K$537.0K$1.4M$1.2M
Net income $316.9M$444.1M$281.6M$202.1M$402.7M$129.1M-$72.2M-$80.3M$63.0M-$103.0M
EPS, basic 2.643.502.131.482.860.95-0.50-0.560.46-0.81
EPS, diluted 2.563.432.101.442.740.91-0.50-0.560.45-0.81
Shares, diluted (wtd. avg.) 123.9M129.4M134.2M140.6M146.8M141.5M144.3M143.6M139.1M128.0M

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents $133.8M$115.8M$118.4M$234.7M$119.2M$148.2M$120.7M$58.4M$169.2M$67.3M
Short-term investments ———$128.6M$622.2M$220.3M$301.1M———
Receivables $426.3M$288.2M$233.3M$231.1M$91.0M$97.7M$59.4M$30.0M$22.1M$15.7M
Inventory $176.5M$141.9M$127.6M$100.1M$53.9M$60.7M$29.4M$22.6M$5.1M$14.6M
Total current assets $825.2M$1.09B$746.4M$739.0M$926.3M$554.8M$543.4M$427.8M$510.4M$256.5M
Property, plant and equipment $44.4M$40.9M$38.1M$35.1M$6.8M$7.3M$10.9M$7.5M$3.5M$4.3M
Goodwill $580.4M$416.8M$416.8M$409.0M$0—————
Other intangibles $981.5M$401.8M$472.9M$546.7M$0—————
Total assets $2.53B$2.06B$1.73B$1.84B$1.10B$579.9M$565.9M$440.2M$519.9M$261.5M
Accounts payable $20.9M$10.2M$11.8M$17.7M$1.5M$1.9M$6.4M$4.1M$7.9M$3.6M
Short-term debt $0$0$0$13.3M$89.4M$397.2M$19.5M$91.5M$77.2M$17.4M
Total current liabilities $177.1M$139.1M$112.5M$130.8M$117.1M$421.4M$85.6M$149.4M$131.3M$54.6M
Long-term debt $2.14B$1.51B$1.50B$1.49B$787.3M$0$383.0M$34.9M$125.1M$199.2M
Total liabilities $2.48B$1.70B$1.65B$1.67B——————
Retained earnings $54.8M$359.9M$90.5M$143.2M-$58.9M-$474.6M-$603.7M-$531.4M-$522.4M-$585.3M
Total equity $48.8M$363.8M$83.8M$169.8M$197.0M$151.0M$91.8M$248.9M$208.4M-$32.5M

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Operating cash flow $651.6M$479.1M$388.6M$240.1M$299.4M$55.5M-$85.4M-$49.5M$134.1M-$50.4M
Depreciation and amortisation $11.4M$10.3M$11.1M$6.5M$3.0M$3.3M$4.1M$2.4M$2.2M$2.4M
Stock-based compensation $51.6M$43.4M$36.6M$24.4M$20.8M$17.2M$34.8M$35.7M$30.7M$25.6M
Capital expenditure $7.0M$10.7M$15.3M$4.8M$1.5M$2.5M$4.0M$4.7M$1.4M$3.1M
Investing cash flow -$545.8M-$262.7M-$96.9M-$487.0M-$406.3M$78.4M-$5.5M$2.5M-$163.7M-$76.8M
Financing cash flow -$85.2M-$218.9M-$408.0M$362.4M$77.9M-$106.3M$153.2M-$63.8M$131.7M$150.6M
Buybacks $342.4M$250.0M$402.4M$200.0M$350.1M$150.1M$200.0M$0$0—

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001159036-26-000024.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. -500M 0 500M 1B 1.5B Revenue, FY2016: 146.7M Gross profit, FY2016: 113.5M Net income, FY2016: -103M Revenue, FY2017: 316.6M Gross profit, FY2017: 285.5M Net income, FY2017: 63M Revenue, FY2018: 151.9M Gross profit, FY2018: 141.7M Net income, FY2018: -80.3M Revenue, FY2019: 196M Gross profit, FY2019: 150.4M Net income, FY2019: -72.2M Revenue, FY2020: 267.6M Gross profit, FY2020: 224.2M Net income, FY2020: 129.1M Revenue, FY2021: 443.3M Gross profit, FY2021: 361.9M Net income, FY2021: 402.7M Revenue, FY2022: 660.1M Gross profit, FY2022: 520.8M Net income, FY2022: 202.1M Revenue, FY2023: 829.3M Gross profit, FY2023: 636.9M Net income, FY2023: 281.6M Revenue, FY2024: 1B Gross profit, FY2024: 855.9M Net income, FY2024: 444.1M Revenue, FY2025: 1.4B Gross profit, FY2025: 1.2B Net income, FY2025: 316.9M FY2016 FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue $146.7M $316.6M $151.9M $196.0M $267.6M $443.3M $660.1M $829.3M $1.02B $1.40B
Gross profit $113.5M $285.5M $141.7M $150.4M $224.2M $361.9M $520.8M $636.9M $855.9M $1.17B
Net income -$103.0M $63.0M -$80.3M -$72.2M $129.1M $402.7M $202.1M $281.6M $444.1M $316.9M

Recent filings and events

  • Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
  • Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
  • Officer or director change Item 5.02
  • Results announced Item 2.02
  • Shareholder vote The results of the annual meeting or a special vote. Item 5.07
  • Officer or director change Item 5.02
  • Charter or fiscal year changed A change to the company's governing documents, or to when its year ends. Item 5.03
  • Officer or director change Item 5.02
  • Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
  • Results announced Item 2.02
  • Results announced Item 2.02
  • Officer or director change Item 5.02

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 2836

TickerCompanyMarket capP/ERevenue growth
AMGN AMGEN INC $237.48B 30.9x 10.0%
GILD GILEAD SCIENCES, INC. $193.48B 23.0x 2.4%
MRNA Moderna, Inc. $79.89B — -39.9%
RVMD Revolution Medicines, Inc. $40.08B — —
BIIB BIOGEN INC. $37.01B 28.5x 2.2%
EXEL EXELIXIS, INC. $15.99B 23.2x 7.0%
NBIX NEUROCRINE BIOSCIENCES INC $14.51B 30.6x 21.4%
TECH BIO-TECHNE Corp $11.38B 62.5x -0.4%